M&T Bank Corp Reduces Stock Position in Catalent, Inc. (NYSE:CTLT)

M&T Bank Corp decreased its stake in shares of Catalent, Inc. (NYSE:CTLT) by 21.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,806 shares of the company’s stock after selling 2,911 shares during the period. M&T Bank Corp’s holdings in Catalent were worth $485,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Tokio Marine Asset Management Co. Ltd. grew its holdings in Catalent by 6.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after purchasing an additional 331 shares during the period. Teacher Retirement System of Texas lifted its holdings in Catalent by 2.6% during the third quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company’s stock valued at $636,000 after purchasing an additional 350 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Catalent by 0.7% in the fourth quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after purchasing an additional 365 shares during the period. Treasurer of the State of North Carolina raised its position in shares of Catalent by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 81,729 shares of the company’s stock valued at $3,721,000 after purchasing an additional 421 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of Catalent by 2.3% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 18,907 shares of the company’s stock valued at $849,000 after buying an additional 434 shares in the last quarter.

Catalent Stock Down 0.5 %

Catalent stock opened at $55.52 on Wednesday. The business’s 50-day simple moving average is $56.26 and its two-hundred day simple moving average is $49.80. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The company has a market cap of $10.05 billion, a PE ratio of -9.10, a PEG ratio of 6.73 and a beta of 1.18. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $60.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Equities analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Barclays raised their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. UBS Group reissued a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens reiterated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Finally, StockNews.com began coverage on Catalent in a research note on Monday. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Catalent has an average rating of “Hold” and a consensus target price of $52.46.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.